STEREOSELECTIVE DISPOSITION OF (+/-)-SOTALOL AT STEADY-STATE CONDITIONS

被引:16
作者
FISET, C
PHILIPPON, F
GILBERT, M
TURGEON, J
机构
[1] HOP LAVAL,INST CARDIOL QUEBEC,ST FOY,PQ,CANADA
[2] UNIV LAVAL,ECOLE PHARM,QUEBEC CITY G1K 7P4,QUEBEC,CANADA
关键词
SOTALOL; STEREOSELECTIVITY; PHARMACOKINETICS; STEADY-STATE;
D O I
10.1111/j.1365-2125.1993.tb05896.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The objective of this study was to assess, under steady-state conditions, the stereoselective disposition of (+/-)-sotalol in man. In all patients studied (n = 7) values of oral clearance (137 +/- 51 ml min-1), renal clearance (96 +/- 42 ml min-1) and nonrenal clearance (41 +/- 25 ml min-1) of (-)-sotalol were greater than those for (+)-sotalol (123 +/- 45 ml min-1, 89 +/- 39 ml min-1 and 34 +/- 23 ml min-1, respectively; P < 0.05, Student's paired t-test). Binding to plasma proteins was greater for (+)-sotalol (38 +/- 9% vs 35 +/- 9% for the (-)-enantiomer; P < 0.05) such that unbound oral clearance (+)/(-) ratio (0.95 +/- 0.06) and unbound renal clearance (+)/(-) ratio (0.97 +/- 0.06) were not stereoselective. In contrast, estimated unbound nonrenal clearance, which represents almost-equal-to 25% of the total unbound clearance of the drug, was greater for the (-)-enantiomer (64 +/- 42 ml min-1) compared with (+)-sotalol (57 +/- 42 ml min-1; P < 0.05). The difference in the pharmacokinetics of sotalol enantiomers is mainly related to stereoselectivity in plasma protein binding.
引用
收藏
页码:75 / 77
页数:3
相关论文
共 15 条
[1]  
ANTTILA M, 1976, ACTA PHARMACOL TOX, V39, P118
[2]  
CARR RA, 1991, PHARMACEUT RES, V8, P195
[3]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[4]   STEREOSELECTIVE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY FOR THE DETERMINATION OF SOTALOL ENANTIOMERS IN BIOLOGICAL-FLUIDS [J].
FISET, C ;
PHILIPPON, F ;
GILBERT, M ;
TURGEON, J .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1993, 612 (02) :231-237
[5]  
FITZ GERALD JD, 1969, CLIN PHARMACOL THER, V10, P292
[6]  
Gibaldi M., 1982, PHARMACOKINETICS, V2nd ed., P409
[7]  
GIUDICELLI JF, 1973, J PHARMACOL-PARIS, V4, P129
[8]  
HAFNER D, 1988, ARZNEIMITTEL-FORSCH, V38-1, P231
[9]   ELECTROPHYSIOLOGIC EFFECTS OF THE LEVOROTATORY AND DEXTROROTATORY ISOMERS OF SOTALOL IN ISOLATED CARDIAC-MUSCLE AND THEIR INVIVO PHARMACOKINETICS [J].
KATO, R ;
IKEDA, N ;
YABEK, SM ;
KANNAN, R ;
SINGH, BN .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1986, 7 (01) :116-125
[10]   THE PHARMACOKINETICS OF D-SOTALOL AND D,L-SOTALOL IN HEALTHY-VOLUNTEERS [J].
POIRIER, JM ;
JAILLON, P ;
LECOCQ, B ;
LECOCQ, V ;
FERRY, A ;
CHEYMOL, G .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1990, 38 (06) :579-582